BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 25554240)

  • 1. Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy.
    Aikawa NE; França IL; Ribeiro AC; Sallum AM; Bonfa E; Silva CA
    Vaccine; 2015 Jan; 33(5):604-9. PubMed ID: 25554240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis.
    Kapetanovic MC; Saxne T; Sjöholm A; Truedsson L; Jönsson G; Geborek P
    Rheumatology (Oxford); 2006 Jan; 45(1):106-11. PubMed ID: 16287919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of anti-TNF treatment on the immunogenicity and safety of the 7-valent conjugate pneumococcal vaccine in children with juvenile idiopathic arthritis.
    Farmaki E; Kanakoudi-Tsakalidou F; Spoulou V; Trachana M; Pratsidou-Gertsi P; Tritsoni M; Theodoridou M
    Vaccine; 2010 Jul; 28(31):5109-13. PubMed ID: 20470802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors.
    Kapetanovic MC; Roseman C; Jönsson G; Truedsson L; Saxne T; Geborek P
    Arthritis Rheum; 2011 Dec; 63(12):3723-32. PubMed ID: 21834061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
    Otten MH; Prince FH; Armbrust W; ten Cate R; Hoppenreijs EP; Twilt M; Koopman-Keemink Y; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
    JAMA; 2011 Dec; 306(21):2340-7. PubMed ID: 22056397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry.
    Horneff G; De Bock F; Foeldvari I; Girschick HJ; Michels H; Moebius D; Schmeling H;
    Ann Rheum Dis; 2009 Apr; 68(4):519-25. PubMed ID: 18413440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis.
    Tynjälä P; Lahdenne P; Vähäsalo P; Kautiainen H; Honkanen V
    Ann Rheum Dis; 2006 Aug; 65(8):1044-9. PubMed ID: 16449314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
    Tynjälä P; Vähäsalo P; Honkanen V; Lahdenne P
    Ann Rheum Dis; 2009 Apr; 68(4):552-7. PubMed ID: 18467515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients.
    Kapetanovic MC; Saxne T; Nilsson JA; Geborek P
    Rheumatology (Oxford); 2007 Apr; 46(4):608-11. PubMed ID: 17114801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept.
    Borte S; Liebert UG; Borte M; Sack U
    Rheumatology (Oxford); 2009 Feb; 48(2):144-8. PubMed ID: 19074187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and persistence of a prime-boost re-vaccination strategy for pneumococcal vaccines in patients with rheumatoid arthritis.
    Bahuaud M; Beaudouin-Bazire C; Husson M; Molto A; Launay O; Batteux F; Dougados M
    Hum Vaccin Immunother; 2018 Jun; 14(6):1464-1470. PubMed ID: 29432051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.
    Elkayam O; Caspi D; Reitblatt T; Charboneau D; Rubins JB
    Semin Arthritis Rheum; 2004 Feb; 33(4):283-8. PubMed ID: 14978666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics of the long-term antibody response after meningococcal C vaccination in patients with juvenile idiopathic arthritis: a retrospective cohort study.
    Stoof SP; Heijstek MW; Sijssens KM; van der Klis F; Sanders EA; Teunis PF; Wulffraat NM; Berbers GA
    Ann Rheum Dis; 2014 Apr; 73(4):728-34. PubMed ID: 23505231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.
    Otten MH; Anink J; Prince FH; Twilt M; Vastert SJ; ten Cate R; Hoppenreijs EP; Armbrust W; Gorter SL; van Pelt PA; Kamphuis SS; Dolman KM; Swart JF; van den Berg JM; Koopman-Keemink Y; van Rossum MA; Wulffraat NM; van Suijlekom-Smit LW
    Ann Rheum Dis; 2015 Jul; 74(7):1379-86. PubMed ID: 24641940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etanercept improves lipid profile and oxidative stress measures in patients with juvenile idiopathic arthritis.
    De Sanctis S; Marcovecchio ML; Gaspari S; Del Torto M; Mohn A; Chiarelli F; Breda L
    J Rheumatol; 2013 Jun; 40(6):943-8. PubMed ID: 23547210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents.
    Russo RA; Katsicas MM
    J Rheumatol; 2009 May; 36(5):1078-82. PubMed ID: 19435972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of long-term etanercept in the treatment of methotrexate-refractory polyarticular-course juvenile idiopathic arthritis in Japan.
    Mori M; Takei S; Imagawa T; Imanaka H; Nerome Y; Higuchi R; Kawano Y; Yokota S; Sugiyama N; Yuasa H; Fletcher T; Wajdula JS
    Mod Rheumatol; 2012 Sep; 22(5):720-6. PubMed ID: 22212889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents.
    Lurati A; Pontikaki I; Teruzzi B; Desiati F; Gerloni V; Gattinara M; Cimaz R; Fantini F
    Arthritis Rheum; 2006 May; 54(5):1602-7. PubMed ID: 16646003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heptavalent pneumococcal conjugate vaccine elicits similar antibody response as standard 23-valent polysaccharide vaccine in adult patients with RA treated with immunomodulating drugs.
    Kapetanovic MC; Roseman C; Jönsson G; Truedsson L
    Clin Rheumatol; 2011 Dec; 30(12):1555-61. PubMed ID: 21956234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokine Biomarkers of Disease Activity and Therapeutic Response after Initiating Methotrexate Therapy in Patients with Juvenile Idiopathic Arthritis.
    Funk RS; Chan MA; Becker ML
    Pharmacotherapy; 2017 Jun; 37(6):700-711. PubMed ID: 28475276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.